Clinical Trial Results:
Clinical Phase II Trial to evaluate efficacy and safety of CD34+ cells mobilization and collection after treatment with plerixafor and filgrastim in patients with Fanconi anemia for subsequent transduction with a lentiviral vector carring FANCA gene and reinfusion in the patient
Summary
|
|
EudraCT number |
2011-006197-88 |
Trial protocol |
ES |
Global end of trial date |
30 Nov 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Oct 2021
|
First version publication date |
04 Oct 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
FANCOSTEM-1
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02931071 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
VHIR
|
||
Sponsor organisation address |
Passeig Vall Hebron 119-129, Barcelona, Spain, 08035
|
||
Public contact |
Joaquin Lopez Soriano, VHIR, 0034 934894865, joaquin.lopez.soriano@vhir.org
|
||
Scientific contact |
Cristina Díaz de Heredia Rubio, VHIR, 0034 934893093, crdiaz@vhebron.net
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Nov 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
30 Nov 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Nov 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective is to assess the safety of cell mobilization after treatment with filgrastim and plerixafor in patients with Fanconi Anemia.
|
||
Protection of trial subjects |
This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial subjects
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Sep 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 11
|
||
Worldwide total number of subjects |
11
|
||
EEA total number of subjects |
11
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
9
|
||
Adolescents (12-17 years) |
2
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
- | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
- | ||||||||||||
Pre-assignment period milestones
|
|||||||||||||
Number of subjects started |
11 | ||||||||||||
Number of subjects completed |
11 | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Arm title
|
CD34+ cells mobilization, collection and immunoselection | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Filgrastim
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection in vial
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
12 microgram/Kg/12 hours, subcutaneous days 0 to 5
|
||||||||||||
Investigational medicinal product name |
Plerixafor
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection in vial
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
240 microgram/kg/day subcutaneous at days 5 to 8
|
||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Efficacy and safety of cell yield
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
After screening, 11 patients were treated with filgrastim and plerixafor for mobilization of CD34+ cells. 9 patients satisfactorily mobilized cells and underwent cell collection. After collection, cells were sorted
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
CD34+ cells mobilization, collection and immunoselection
|
||
Reporting group description |
- | ||
Subject analysis set title |
Efficacy and safety of cell yield
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
After screening, 11 patients were treated with filgrastim and plerixafor for mobilization of CD34+ cells. 9 patients satisfactorily mobilized cells and underwent cell collection. After collection, cells were sorted
|
|
|||||||
End point title |
Safety [1] | ||||||
End point description |
|||||||
End point type |
Primary
|
||||||
End point timeframe |
12 months follow-up after cell mobilization
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Goal of the study was to evaluate the safety of the procedure for mobilizing and collecting CD34 cells. There were no treatments in separate arms or periods to justify an statistical analysis. No procedure-associated serious adverse events were observed. Safety of the procedure is included in the adverse events section |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Patients with CD34 cell threshold mobilized | ||||||||
End point description |
> or = to 5 CD34 cell/microliter
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
After tretament with filgrastim and plerixafor
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
CD34 cell collected | ||||||||
End point description |
Number of patients with efficient collection of cells after apheresis, > or = to 4x10^6 cells/kg body weight (projections of body weight after 5 years)
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
After apheresis collection
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
CD34 cell immunoselected | ||||||||
End point description |
Recovery of CD34 cells after immunoselection has to be > or = to 50%
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
After mobiliation, collection, and immunoselection
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Global efficacy of the procedure | ||||||||
End point description |
Patients achieving > or = 4x10^6 CD34 cells/kg, projecting body weight at 5 years
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
After completing the procedure
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
The whole study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Drug-related
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Total adverse events
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
01 Mar 2015 |
Change of sponsor from Cristina Díaz de Heredia to VHIR
Change of CRO from Quantum to Sermes
Modification of hour of administration of plerixafor, closer to the apheresis procedure
Modification of consent forms
Modification in pharmaceutical form of filgrastrim to vials for injection
Filgrastim datasheet was added to documentation |
||
06 Sep 2017 |
Sample size and recruitment period were expanded |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Although the threshold of CD34 immunoselected cells was not achieved, enough number of cells were obtained for gene correction and engraftment. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/34485595 |